tocilizumab,obinutuzumab,glofitamab
jw pharma,roche
['dlbcl', 'lymphoma', 'lymsm', 'glofitamab', 'follicular']
glofitamab has been approved by the fda for dlbcl, nos or transformed follicular lymphoma after 2 lines of therapy. a fixed- duration therapy for patients! suspect it will become a post-car option in sequencing. #lymsm #17icml 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈